Innovent Biologics, Inc.

As of December 31, 2025, Innovent Biologics, Inc. carries a market capitalization of 132.27B, placing it among publicly traded companies globally. Its enterprise value stands at 115.11B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Innovent Biologics, Inc.'s next confirmed earnings release is scheduled for March 31, 2027.

As of December 31, 2025, Innovent Biologics, Inc. has 1.73B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Innovent Biologics, Inc. maintains a current ratio of 2.62, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 23, 2026, Innovent Biologics, Inc.'s stock has declined approximately 2.23% over the past 52 weeks. The 50-day moving average sits at 97.00, while the 200-day moving average is 87.92.

As of December 31, 2025, Innovent Biologics, Inc. holds 20.29B in cash and equivalents against 3.13B in total debt, resulting in a net debt position of -16.21B. Total book value stands at 21.54B, with working capital of 15.17B providing operational flexibility.